CBD who’s who: New Leaf Pharmaceuticals
New Leaf Pharmaceuticals has been manufacturing nasal sprays for 20 years. The Newtown, Conn.-based company recently announced the launch of Rhinodol nasal spray, delivering the CBD using a transmucosal technique to ensure the highest bioavailability possible. Bioavailability refers to the amount of a drug that is absorbed and available for use in the body compared with the amount of drug delivered or administered. Bioavailability varies depending on the route of administration. CBD is a fat-soluble substance and has poor bioavailability when administered orally through the stomach and gut. The company said the most optimal route of CBD administration has proven to be transmucosal or intranasal, with between 48% and 62% being absorbed and available for use in the body.
“We have products that are very effective and have good bioavailability at a price point the consumer feels they can reach,” said Paul Carpenter, partner and founding member of New Leaf Pharmaceuticals. “If they are trying a $10 or $15 product that you swallow and the absorption rate is 8% to 12%, it’s not going to be effective, and you lose them forever.”
“We have products that are very effective and have good bioavailability at a price point the consumer feels they can reach,” said Paul Carpenter, partner and founding member of New Leaf Pharmaceuticals. “If they are trying a $10 or $15 product that you swallow and the absorption rate is 8% to 12%, it’s not going to be effective, and you lose them forever.”